通过天眼查大数据分析，椎元医学技术（上海）有限公司知识产权方面有商标信息13条，专利信息11 条，此外企业还拥有行政许可1个。 天眼查信息显示，椎元医学技术（上海）有限公司的股东为：上海赛立维生物科技有限公司、上海强基 企业管理合伙企业（有限合伙）、上海凯利泰医疗科技股份有限公司、杭州泽悦子宁创业投资合伙企业 （有限合伙）、上海张科禾苗创业投资合伙企业（有限合伙）。 来源：市场资讯 2月12日，天眼查融资历程显示，椎元医学技术（上海）有限公司近日获得"A轮"融资，涉及融资金额 2000万人民币，投资机构为三友医疗。 资料显示，椎元医学技术（上海）有限公司法定代表人为范明，成立于2021年，位于上海市，是一家以 从事研究和试验发展为主的企业。企业注册资本523.5102万人民币，并已于2026年完成了A轮，交易金 额2000万人民币。 ...

Group 1 - The core viewpoint of the news is that Lepu Medical (300003) is expected to see a significant increase in net profit in 2025, driven by a recovery in traditional business and breakthroughs in the medical aesthetics sector [1][2] - The company forecasts a net profit of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95%, ending a previous trend of decline [1] - The medical aesthetics business, particularly the Tongyan needle product, has rapidly gained traction since its launch in August 2025, generating approximately 100 million yuan in revenue by October 2025 [1] Group 2 - The financial report indicates that the growth in net profit is primarily due to the stabilization of traditional business and contributions from emerging sectors, with core cardiovascular intervention revenue showing steady growth [2] - The retail channel inventory for the pharmaceutical segment has been cleared, leading to double-digit growth in formulation revenue, while innovative drugs and medical aesthetics have become new sources of revenue [2] - The company expects a nearly 95% increase in net cash flow from operating activities, with a stable debt-to-asset ratio of 31%, indicating a solid financial position [2] Group 3 - Recently, Lepu Medical's stock price has shown limited volatility, closing at 17.98 yuan on February 11, 2026, with a slight decline of 0.17% on that day [3] - Over a 5-day period, the stock has seen a minor increase of 0.11%, but a notable decline of 11.38% over 20 days indicates short-term fluctuations [3] - The stock is positioned near the lower band of the Bollinger Bands, with weak MACD indicators, although the 60-day moving average provides support [3]

| 北证日均成交额环比继续下降，北证 50 | | --- | | 指数当周震荡显著 | ——北交所周报（2026 年 2 月第 1 周） 本报告导读： 2 月第 1 周 A 股市场缩量震荡，小盘股表现稍弱，北证 50 指数波动明显，单周小幅 下跌 0.70%，日均成交额回落至 200 亿元附近。当周北交所 2 只新股招股，无新股 上市。 次新板块持续回调，科创板年内首只未盈利新股 上市 2026.02.10 新股精要—动力电池热失控防护零部件领先提供 商固德电材 2026.02.10 IPO 月度数据一览（2026 年 1 月） 2026.02.03 次新板块回调明显，恒运昌申购收益亮眼 2026.02.02 北证交易活跃度回升，北证 50 指数回调 2026.02.01 证 券 研 究 报 告 投资要点： 新股研究 /[Table_Date] 2026.02.12 | [Table_Authors] | 王政之(分析师) | | --- | --- | | | 021-38674944 | | | wangzhengzhi@gtht.com | | 登记编号 | S0880517060002 | | | ...

Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. is the first innovative medical device company to be accepted for IPO under the fifth set of listing standards of the Sci-Tech Innovation Board, aiming to raise 1.217 billion yuan for various projects, including R&D and marketing network development [1][6] Group 1: Company Overview - Core Medical is a leader in China's artificial heart industry, holding multiple "first" titles [4] - The company has several products included in China's special review process for innovative medical devices, leading the field in terms of the number of products [5] - The Corheart 6, the world's smallest and lightest commercialized magnetic levitation implantable artificial heart, was approved for market in June 2023, with a projected market share of over 45% in 2024 [5] Group 2: Financial Performance - The company reported revenues of 16.55 million yuan, 93.69 million yuan, and 70.48 million yuan for the years 2023, 2024, and the first half of 2025, respectively, with net losses of 170 million yuan, 132 million yuan, and 72.75 million yuan during the same periods [8] - Cumulative losses since 2022 have exceeded 500 million yuan [8] - Gross margins for the reporting periods were 66.25%, 69.66%, and 72.09%, consistent with industry averages [9] Group 3: Investment and Financing - Prior to the IPO, Core Medical attracted investments from several prominent institutions, including Hillhouse Capital and Zhengxin Valley Investment [2][14] - The company completed a D-round financing of over 100 million USD in April 2025, marking the largest market-based financing in China's innovative medical device sector for that year [16]

Core Viewpoint - The article emphasizes the importance of ensuring the safety of pharmaceuticals and medical devices during the winter season through a regulatory initiative in Xinjiang Shawan City, aimed at protecting public health [1] Group 1: Regulatory Actions - The Xinjiang Shawan City Market Supervision Administration is conducting a "100-day rectification action" focused on the quality and safety of pharmaceuticals and medical devices during winter [1] - The initiative targets pharmaceutical and medical device businesses, verifying the validity of operating licenses, legality of procurement channels, compliance in storage and maintenance, and completeness of incoming inspection [1] Group 2: Focus Areas - Key areas of focus include cold-chain pharmaceuticals, traditional Chinese medicine pieces, and commonly used medical devices [1] - The enforcement personnel are combining law enforcement with service, providing on-site guidance for businesses to standardize management and assisting with license changes [1] Group 3: Future Plans - The Xinjiang Shawan City Market Supervision Administration plans to continue enhancing precise regulation and warm service to further advance the "100-day rectification action" for pharmaceutical and medical device quality and safety [1] - The initiative aims to reinforce the primary responsibility of enterprises, ensuring that the public can use medications and medical devices with greater confidence during the winter [1]

Core Viewpoint - Anxu Bio (688075) has disclosed its 2025 performance forecast, expecting a significant decline in net profit and a delay in its fundraising project until 2027 [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan, representing a year-on-year decrease of 55.80% to 63.08% [2] - The expected non-recurring net profit is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [2] - The performance decline is primarily attributed to increased tariffs in the U.S. leading to reduced orders, foreign exchange losses due to currency fluctuations, decreased interest income, and asset depreciation [2] Project Progress - The company announced on January 30, 2026, that the completion date for its "in vitro diagnostic reagents and diagnostic instruments R&D and production project" has been postponed from January 2026 to January 2027 [3] - The delay is attributed to the impact of global respiratory infectious diseases on renovation progress and delays in equipment investment [3] Company Status - Shareholder Ma Huaxiang reduced his stake in the company by selling 804,500 shares between January 6 and January 21, 2026, decreasing his holding from 11.62% to 10.99%, which has reached the 1% threshold for equity change [4] Business and Technical Development - The company is actively transitioning from a single product focus to a comprehensive health management approach, including the expansion of pet testing products and chronic disease management apps [5] - The company is deepening its overseas market presence, with multiple international certifications expected in 2025, although related investments may lead to increased short-term expenses [5]

Group 1 - The Hong Kong innovative drug concept stocks have declined, with companies such as 3SBio, Kelun-Botai Biopharmaceuticals falling over 3%, and CSPC Pharmaceutical Group, China Biologic Products, and Hansoh Pharmaceutical dropping over 2% [1] - The Hong Kong innovative drug-related ETFs have also seen a decline of over 2% [1] Group 2 - Current analysis indicates that the healthcare sector presents multiple investment opportunities, with the CXO industry experiencing sustained improvement due to a recovery in overseas orders and domestic capacity reduction, while still having room for valuation recovery [2] - The medical device sector is benefiting from domestic equipment upgrade policies and overseas market expansion, with continuous catalysts in cutting-edge areas such as brain-computer interfaces and AI imaging [2] - Internet healthcare is seeing improved operational efficiency in the context of deepening medical insurance payment reforms, leading to a clearer profit growth trajectory [2]

Group 1 - The core viewpoint of the article highlights the recent stock price fluctuations of Kangtong Medical, with a notable decline in share price and net outflow of funds, indicating potential investor concerns [1] - As of February 11, the closing price was 25.44 yuan, down 0.70% from the previous day, with a trading volume of 3,882 million yuan and a turnover rate of 2.32% [1] - The company operates in brain-computer interfaces, smart medical devices, and medical equipment, showing potential applications in surgical environments [1] Group 2 - A recent report by the China Academy of Information and Communications Technology emphasizes the trend of AI medical equipment in precision medicine and grassroots healthcare, which may provide long-term benefits to the medical device sector [2] - The collaboration proposal between Nansha and Hong Kong to build a biopharmaceutical industry cluster may indirectly boost the attention on regional medical innovation enterprises [2] Group 3 - For the period from January to September 2025, the company's operating revenue was 344 million yuan, a year-on-year decrease of 30.06%, while the net profit attributable to shareholders was a loss of 10.21 million yuan, down 150.92% year-on-year [3] - The number of shareholders decreased by 4.48% compared to the previous period, indicating a slight increase in share concentration [3]

Core Viewpoint - The medical innovation sector is experiencing growth, highlighted by the successful debut of China's first fully self-developed orthopedic surgical robot, indicating advancements in medical technology and potential investment opportunities in the sector [1][2]. Group 1: Market Performance - As of February 12, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.05%, with notable gains from companies such as WuXi AppTec (up 3.39%) and Kanglong Chemical (up 1.37%) [1]. - The Medical Innovation ETF (516820) is currently priced at 0.37 yuan, with a trading volume of 794.40 million yuan and a turnover rate of 0.42% [1]. - Over the past month, the average daily trading volume of the Medical Innovation ETF was 65.14 million yuan [1]. Group 2: Industry Insights - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2]. - The global market for surgical robots is estimated to exceed 1 trillion yuan, with significant growth potential in penetration rates and market size [2]. - Domestic leaders in the surgical robot market are accelerating product iterations, achieving performance levels close to global leaders, and have a substantial portion of their revenue from overseas markets, which are experiencing high growth [2]. - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - Tianzhihang Medical Technology Co., Ltd. experienced a stock price increase of 5.43%, reaching 26.19 CNY per share, with a trading volume of 165 million CNY and a turnover rate of 1.42%, resulting in a total market capitalization of 11.942 billion CNY [1] - The company, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots [1] - The revenue composition of the company includes: orthopedic surgical navigation robots (58.31%), supporting equipment and consumables (23.86%), technical services (16.49%), and other (1.31%) [1] Group 2 - Galaxy Fund holds a significant position in Tianzhihang, with the Galaxy Kangle Stock A fund (519673) owning 467,900 shares, representing 5% of the fund's net value, making it the ninth-largest holding [2] - The Galaxy Kangle Stock A fund has a current size of 141 million CNY and has achieved a year-to-date return of 18.34%, ranking 89 out of 5,569 in its category [2] - The fund manager, Fang Wei, has been in charge for 4 years and 280 days, with the fund's total assets amounting to 576 million CNY, and the best and worst returns during his tenure being 2.42% and -12.24%, respectively [2]